Therapeutic Benefits and Risks of MDMA

Guideline-Based Position

The U.S. Department of Veterans Affairs and Department of Defense recommends against the use of MDMA outside of clinical trial settings due to its classification as a drug of abuse and lack of approval for therapeutic use 1

MDMA use increases the risk of both ischemic and hemorrhagic stroke through multiple mechanisms, including acute severe blood pressure elevations, cerebral vasospasm, vasculitis, endothelial dysfunction, and increased platelet aggregation 2
The drug produces hemostatic and hematological abnormalities resulting in increased blood viscosity, which can precipitate acute coronary syndromes and cerebrovascular events 2
Long-term use is associated with progressive myocyte damage and accelerated atherosclerosis 2

The American College of Physicians, as reflected in the Annals of Internal Medicine, recommends that MDMA should not be used therapeutically outside of approved clinical trials due to its cardiovascular risks, neurotoxic effects, abuse potential, and lack of regulatory approval 1

MDMA is categorized as a hallucinogen in medical classification systems, specifically as a phenylisopropylamine alongside other substances with potential for abuse 3, 4

The U.S. Department of Veterans Affairs and Department of Defense clinical practice guideline explicitly recommends against using MDMA and other unapproved pharmacologic agents outside clinical trials 5